Solid Biosciences Inc. filings document regulatory disclosures for a Nasdaq-listed precision genetic medicine company developing gene therapies for rare neuromuscular and cardiac diseases. Its SEC records include Form 8-K reports on operating and financial results, Regulation FD presentations, clinical updates for SGT-003 and the INSPIRE DUCHENNE trial, material agreements, and capital-structure matters.
Proxy filings describe annual stockholder meeting proposals, board classification matters, advisory votes, executive compensation, and equity awards. The filing record also identifies the company’s common stock as listed on The Nasdaq Global Select Market under the SLDB symbol.
Solid Biosciences submitted a Form 144 reporting a proposed sale of 3,616 shares of common stock to settle vested restricted stock units on 02/18/2026.
The filing lists prior sales by the reporting person: 2,701 shares on 12/03/2025, 26,250 shares on 02/02/2026, and 10,905 shares on 02/04/2026. The securities are listed on NASDAQ.
Solid Biosciences Inc. director Ilan Ganot reported 2,658 common shares to be sold, with an aggregate market value of $15,748.33 and an approximate sale date of February 18, 2026. The shares were acquired through settlement of vested restricted stock units indirectly held through his wife, Ms. Ganot. Remarks state the sale was made to cover withholding taxes under a durable automatic sales instruction letter adopted September 25, 2024, and was not a discretionary trade.
Solid Biosciences Inc. Chief Technology Officer Paul Herzich reported both an RSU vesting and a related stock sale. On February 13, 2026, he acquired 7,187 shares of common stock upon the exercise of 7,187 restricted stock units at $0.00 per share, increasing his direct common stock holdings to 76,254 shares.
On February 18, 2026, Herzich then sold 3,616 common shares in an open-market transaction at a weighted average price of $5.8233 per share, with actual prices ranging from $5.23 to $6.14. The company states this sale was solely to cover tax withholding following RSU vesting, under a pre-established automatic sales instruction, and does not represent a discretionary trade by Herzich. After the sale, he directly held 72,638 common shares.
Solid Biosciences Chief Operating Officer David T. Howton reported routine equity activity involving restricted stock units and related share sales. On February 13, 2026, RSUs granted on February 13, 2024 vested, resulting in the acquisition of 14,687 shares of common stock through a derivative conversion at a price of $0.00 per share. A corresponding RSU position of 14,687 units was reduced, leaving 29,376 RSUs outstanding. On February 18, 2026, 7,469 common shares were sold in the open market at a weighted average price of $5.8233 per share to cover withholding taxes following this vesting, under a durable automatic sales instruction adopted on August 16, 2024, so the sale was not a discretionary trade. After these transactions, Howton held 105,077 shares of common stock directly.
Solid Biosciences proposed the sale of common stock under Rule 144 related to the settlement of vested restricted stock units. The filing lists 7,469 shares to be sold on 02/18/2026 as settlement of vested RSUs. It also discloses recent sales by David T. Howton totaling 61,597 shares across 12/03/2025, 02/02/2026, and 02/04/2026, with exact per‑trade share counts shown in the excerpt.
Solid Biosciences Inc. reported insider equity activity by Chief Medical Officer Gabriel Brooks. Previously granted restricted stock units (RSUs) vested, and each RSU converts into one share of common stock. On the vesting date, 10,937 RSUs were exercised into the same number of common shares at no cash exercise price.
A related sale of common stock was executed solely to cover withholding taxes under a pre‑established durable automatic sales instruction adopted on August 15, 2024. The company notes this sell‑to‑cover transaction was not a discretionary trade by Dr. Brooks. Following these transactions, Brooks directly held 89,466 common shares and 21,876 RSUs.
Solid Biosciences reported insider sale activity by Kevin Tan: reported sales include 5,704 shares for $30,060.08 on 01/13/2026, 26,837 shares for $172,747.09 on 02/02/2026, and 14,783 shares for $95,226.63 on 02/04/2026. The filing also records 5,404 shares associated with settlement of vested restricted stock units on 02/18/2026.
Solid Biosciences Inc. Chief Financial Officer and Treasurer Kevin Tan reported RSU vesting and related share activity. On February 13, 2026, 10,625 restricted stock units converted into 10,625 shares of common stock at no cost, leaving 21,250 RSUs outstanding and 104,826 common shares held directly.
On February 18, 2026, Tan sold 5,404 common shares at a weighted average price of $5.8233 per share to cover withholding taxes after the RSU vesting, under a durable automatic sales instruction adopted on August 15, 2024. The sale was not a discretionary trade, and he now directly holds 99,422 common shares.
Solid Biosciences Inc. received a Schedule 13G reporting that investment adviser Vestal Point Capital, LP and its Chief Investment Officer Ryan Wilder beneficially own 5,815,000 shares of common stock. This represents 7.5% of the outstanding shares, based on 77,910,239 shares outstanding as of October 29, 2025.
The shares are held through a fund and managed account advised by Vestal Point Capital. The filing states the holdings were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Solid Biosciences.
Solid Biosciences Inc. received an updated ownership disclosure from Adage Capital affiliates. Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 1,400,000 shares of Solid Biosciences common stock, representing 1.80% of the outstanding shares as of October 29, 2025.
The shares are held through Adage Capital Partners, L.P., with shared voting and dispositive power and no sole voting or dispositive power reported. The filing is on a passive Schedule 13G/A basis, and the reporting group confirms the position is held in the ordinary course of business and not to change or influence control of the company.